[R01] Personalized Prediction of Atopic Dermatitis Disease Course Across Diverse Settings
Ente: National Institute of Arthritis and Musculoskeletal and Skin Diseases
Scadenza: 2028-06-30
Importo max: 198.645 EUR
Paese: US
Descrizione
PROJECT SUMMARY
Atopic dermatitis often presents in early childhood and is characterized by a heterogeneous disease course:
while some children improve by adolescence, many others continue to have persistent disease and develop
comorbid allergic, neuropsychiatric, and metabolic conditions. Prognostic information is needed for patient
counseling and to improve the efficiency of clinical trials evaluating whether new treatments could impact long-
term outcomes. We propose a series of aims designed to predict which children with early-onset disease are
more likely to develop persistent disease and comorbid conditions. First, using machine learning methods, we
will develop prognostic models for persistent atopic dermatitis in late childhood using a standardized set of
easy-to-measure early life predictors in diverse birth cohorts from Uganda, Ecuador, and the United Kingdom.
We will compare model performance across cohorts and evaluate whether a single, generalized model for
persistent atopic dermatitis could be useful in diverse settings. Second, we will create another set of models for
each cohort adding more detailed predictors such as genetic risk scores, environmental variables and bio
samples that vary across cohorts and may be more costly to measure. We will compare the performance of the
models with an expanded set of predictors to the models that use a more limited set of standardized predictors
within each cohort to better understand the nature of data needed for atopic dermatitis risk prediction across
diverse settings. Finally, we will expand the prognostic models to additionally capture atopic dermatitis
comorbidities, including other allergic diseases such as asthma and allergies; neuropsychiatric conditions such
as anxiety, depression, and attention-deficit hyperactivity disorder; and metabolic disorders such as diabetes,
dyslipidemia, obesity and hypertension. The results will offer useful prognostic information for patients, address
a critical need for atopic dermatitis research among diverse populations, and enable targeted enrollment to
improve the efficiency of clinical trials. This is particularly timely because the FDA has endorsed the use of
tools designed to enroll patients most likely to demonstrate disease persistence, and there are many new
systemic treatments under development for atopic dermatitis that are being tested for children as young as 6
months old.
Istituzione: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
PI: Katrina Elaine Abuabara
Progetto: 5R01AR085315-02
Settori: National Institute of Arthritis and Musculoskeletal and Skin Diseases
Vai al bando originale
Registrati gratis su Bandolo per trovare bandi compatibili con la tua azienda.